[go: up one dir, main page]

WO2016163886A3 - Administration of taurine or an analog thereof for the treatment of nerve cell damage - Google Patents

Administration of taurine or an analog thereof for the treatment of nerve cell damage Download PDF

Info

Publication number
WO2016163886A3
WO2016163886A3 PCT/NL2016/050249 NL2016050249W WO2016163886A3 WO 2016163886 A3 WO2016163886 A3 WO 2016163886A3 NL 2016050249 W NL2016050249 W NL 2016050249W WO 2016163886 A3 WO2016163886 A3 WO 2016163886A3
Authority
WO
WIPO (PCT)
Prior art keywords
taurine
treatment
analog
nerve cell
cell damage
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/NL2016/050249
Other languages
French (fr)
Other versions
WO2016163886A2 (en
Inventor
Annette Klazina OFFRINGA-HUP
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Clues2cure International BV
Original Assignee
Clues2cure International BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Clues2cure International BV filed Critical Clues2cure International BV
Publication of WO2016163886A2 publication Critical patent/WO2016163886A2/en
Publication of WO2016163886A3 publication Critical patent/WO2016163886A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0085—Brain, e.g. brain implants; Spinal cord
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Psychology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention relates to the use of taurine or an analog thereof and/or albumin, for use in the treatment of nerve cell damage. In particular, taurine or a metabolite or precursor thereof and/or albumin may be administered for the treatment of multiple sclerosis, amyotrophic lateral sclerosis, and other neurodegenerative disorders. The compounds may be administered to the central nervous system of an individual in need thereof by a route which bypasses the blood- brain barrier, such as by intraspinal or intrathecal administration. The present invention also relates to the use of taurine or an analog thereof in the treatment of bone disorder or bone injury.
PCT/NL2016/050249 2015-04-10 2016-04-11 Administration of taurine or an analog thereof for the treatment of nerve cell damage Ceased WO2016163886A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15163272 2015-04-10
EP15163272.6 2015-04-10

Publications (2)

Publication Number Publication Date
WO2016163886A2 WO2016163886A2 (en) 2016-10-13
WO2016163886A3 true WO2016163886A3 (en) 2017-02-09

Family

ID=52824140

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/NL2016/050249 Ceased WO2016163886A2 (en) 2015-04-10 2016-04-11 Administration of taurine or an analog thereof for the treatment of nerve cell damage

Country Status (1)

Country Link
WO (1) WO2016163886A2 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20250228998A1 (en) * 2023-06-07 2025-07-17 Acuitive Technologies, Inc. Anionic Citrate-Based Biomaterials

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999040909A1 (en) * 1998-02-11 1999-08-19 Neurochem, Inc. Method for modulating macrophage activation
JPH11279057A (en) * 1998-03-30 1999-10-12 Arimasa Miyamoto NFκB activation inhibitor
WO2010027266A1 (en) * 2008-09-05 2010-03-11 Van De Langenberg, Hendrikus Theodorus Ardina Hubertus Means and methods for counteracting neurological disorders

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07502507A (en) 1991-12-17 1995-03-16 プロクター、エンド、ギャンブル、ファーマスーティカルズ、インコーポレーテッド Method for treating osteoporosis using bisphosphonates and parathyroid hormone
WO2011008982A1 (en) 2009-07-15 2011-01-20 Sah Dinah W Y Treatment of neurological disorders
CA2771175C (en) 2009-08-25 2017-12-05 The Regents Of The Univeristy Of California Optimized placement of cannula for delivery of therapeutics to the brain

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999040909A1 (en) * 1998-02-11 1999-08-19 Neurochem, Inc. Method for modulating macrophage activation
JPH11279057A (en) * 1998-03-30 1999-10-12 Arimasa Miyamoto NFκB activation inhibitor
WO2010027266A1 (en) * 2008-09-05 2010-03-11 Van De Langenberg, Hendrikus Theodorus Ardina Hubertus Means and methods for counteracting neurological disorders

Non-Patent Citations (9)

* Cited by examiner, † Cited by third party
Title
CHUNG ET AL: "Advances in drug design based on the amino Acid approach: taurine analogues for the treatment of CNS diseases", PHARMACEUTICALS, vol. 5, 23 October 2012 (2012-10-23), pages 1128 - 1146, XP002740631 *
FANDEL DANIEL ET AL: "Spinal cord injury induced changes of nuclear receptors PPAR[alpha] and LXR[beta] and modulation with oleic acid/albumin t", BRAIN RESEARCH, vol. 1535, October 2013 (2013-10-01), pages 89 - 105, XP028727980, ISSN: 0006-8993, DOI: 10.1016/J.BRAINRES.2013.08.022 *
GUPTA R C: "Taurine analogues and taurine transport: therapeutic advantages", ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY, vol. 583, 1 January 2006 (2006-01-01), SPRINGER, US, pages 449 - 467, XP009192550, ISSN: 0065-2598 *
HAYATE JAVED ET AL: "Taurine ameliorates neurobehavioral, neurochemical and immunohistochemical changes in sporadic dementia of Alzheimer's type (SDAT) caused by intracerebroventricular streptozotocin in rats", NEUROLOGICAL SCIENCES, vol. 34, no. 12, 1 December 2013 (2013-12-01), pages 2181 - 2192, XP055194386, ISSN: 1590-1874, DOI: 10.1007/s10072-013-1444-3 *
JANET MENZIE ET AL: "Taurine and central nervous system disorders", AMINO ACIDS, vol. 46, no. 1, 19 August 2012 (2012-08-19), pages 31 - 46, XP055194394, ISSN: 0939-4451, DOI: 10.1007/s00726-012-1382-z *
L. BELAYEV ET AL: "Albumin Therapy of Transient Focal Cerebral Ischemia: In Vivo Analysis of Dynamic Microvascular Responses", STROKE, vol. 33, no. 4, 1 April 2002 (2002-04-01), US, pages 1077 - 1084, XP055323870, ISSN: 0039-2499, DOI: 10.1161/hs0402.105555 *
STERNBERG Z ET AL: "Acamprosate modulates experimental autoimmune encephalomyelitis", INFLAMMOPHARMACOLOGY, vol. 20, no. 1, 17 November 2011 (2011-11-17), EXPERIMENTAL AND CLINICAL STUDIES - OFFICIAL PUBLICATION OF THE GASTROINTESTINAL SECTION OF THE INTERNATIONAL UNION OF PHARMACOLOGY (IUPHAR), BIRKHÄUSER-VERLAG, BA, pages 39 - 48, XP035009877, ISSN: 1568-5608, DOI: 10.1007/S10787-011-0097-1 *
YASUTOMI CHIGUSA ET AL: "[Anti-osteopenic effect of taurine: possible involvement of activated MEK-ERK-Cbfa1 signaling]", NIPPON YAKURIGAKU ZASSHI - FOLIA PHARMACOLOGICA JAPONICA, NIPPON YAKURI GAKKAI, KYOTO, JP, vol. 120, no. 1, 1 November 2002 (2002-11-01), pages 114P - 115P, XP009192553, ISSN: 0015-5691 *
ZHANG ET AL: "Human albumin prevents 6-hydroxydopamine-induced loss of tryrosine hydroxylase in vitro and in vivo", PLOS ONE, vol. 7, no. 7, E41226, 17 July 2012 (2012-07-17), pages 1 - 13, XP002764700 *

Also Published As

Publication number Publication date
WO2016163886A2 (en) 2016-10-13

Similar Documents

Publication Publication Date Title
WO2018060732A3 (en) Compositions and methods for treating seizure disorders
WO2017075338A3 (en) Delivery of central nervous system targeting polynucleotides
WO2016044556A3 (en) Arginine methyltransferase inhibitors and uses thereof
WO2015066426A3 (en) Angiopoietin-based interventions for treating cerebral malaria
HK1206264A1 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
AU2019268069A1 (en) Methods and compositions for improving cognitive function
WO2014160871A8 (en) Methods and agents for treating alzheimer's disease
WO2014012094A3 (en) Tetracycline compounds for treating neurodegenerative disorders
HK1206726A1 (en) Imidazotriazinone compounds
WO2015171965A3 (en) Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
HK1249500A1 (en) Tricyclic sulfones as ror modulators
MX2016016480A (en) Novel therapeutic uses of benzylideneguanidine derivatives for the treatment of proteopathies.
CL2013002394A1 (en) Compounds derived from substituted 6,7-dialkoxy-3-isoquinolinol, inhibitors of pde10a; pharmaceutical composition that includes them; and its use in the treatment of metabolic disorders, CNS disorders such as Alzheimer's disease, dementia, depression and neurodegenerative disorders such as multiple sclerosis, among others.
EP4086249A3 (en) 6-membered aza-heterocyclic containing delta-opioid receptor modulating compounds, methods of using and making the same
WO2013173827A3 (en) Methods and compositions for inhibiting diseases of the central nervous system
WO2015047982A3 (en) Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof
WO2016106284A3 (en) Creatine prodrugs, compositions and methods of use thereof
WO2017079403A3 (en) Polymeric nanoparticles
MX369451B (en) A crystalline form of an anxiolytic compound.
PH12015501402A1 (en) 4-hydroxy-2-methyl-5-(propan-2-ylidene)cyclohex-3-enecarbaldehyde for the prevention and treatment of a cognitive, neurodegenerative or neuronal disease
PH12015502676A1 (en) 4-(5-(4-chlorophenyl)-2-(2-cyclopropylacetyl)-1,4-dimethyl-1h-pyrrol-3-yl)benzenesulfonamide as alpha 7 nachr modulator
PH12018500300A1 (en) Combination treatment comprising administration of 2-amino-3,5,5-trifluoro-3,4,5,6-tetradropyridines
HK1198423A1 (en) Topical pharmaceutical compositions comprising bexarotene and a corticosteroids
WO2016163886A3 (en) Administration of taurine or an analog thereof for the treatment of nerve cell damage
WO2014197536A3 (en) Novel beta lactams as modulators of glutamate uptake and methods for use thereof

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16731363

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16731363

Country of ref document: EP

Kind code of ref document: A2